Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
XiaoXia WeiHong SunJie ZhuangXiuhua WengBin ZhengQiwang LinGuifeng ZhangJiaqin CaiPublished in: Clinical drug investigation (2020)
From the perspective of the Chinese healthcare system, CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer.